Tonix Pharmaceuticals Holding Past Earnings Performance
Past criteria checks 0/6
Tonix Pharmaceuticals Holding's earnings have been declining at an average annual rate of -8.2%, while the Biotechs industry saw earnings growing at 33.4% annually. Revenues have been growing at an average rate of 62.9% per year.
Key information
-8.22%
Earnings growth rate
38.12%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 62.89% |
| Return on equity | -71.83% |
| Net Margin | -548.64% |
| Last Earnings Update | 30 Jun 2026 |
Recent past performance updates
Recent updates
Fibromyalgia Launch And Lyme Program Will Redefine Long Term Prospects
Catalysts About Tonix Pharmaceuticals Holding Tonix Pharmaceuticals Holding develops and commercializes prescription medicines that target unmet needs in fibromyalgia, migraine, depression and Lyme disease prevention. What are the underlying business or industry changes driving this perspective?
Fibromyalgia Leadership And Lyme Prevention Pipeline Will Drive Compelling Long Term Upside
Catalysts About Tonix Pharmaceuticals Holding Tonix Pharmaceuticals Holding focuses on developing and commercializing treatments and preventatives for conditions with significant unmet medical need, including fibromyalgia, major depressive disorder, and Lyme disease. What are the underlying business or industry changes driving this perspective?Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
As you might know, Tonix Pharmaceuticals Holding Corp. ( NASDAQ:TNXP ) just kicked off its latest quarterly results...Tonix Delivers A Beat, But The Real Test Starts Now
Summary Tonix Pharmaceuticals (TNXP) reported strong 2Q26 results, with $13.5M revenue and early commercial traction for TONMYA, but remains in a spend-to-scale phase. TONMYA prescriptions and refills surged, yet revenue lags due to recent payer coverage; sustained revenue ramp hinges on access translating to reimbursed sales. Operating expenses and cash burn are elevated, with a cash runway into early 2Q27, creating near-term dilution risk despite improving fundamentals. Valuation appears cheap on EV metrics, but equity pricing reflects execution and financing risks; clear proof of scalable, access-driven growth is needed before upgrading from Hold. Read the full article on Seeking Alpha
Fibromyalgia And Lyme Setbacks Will Pressure Margins Yet Long-Term Pipeline Potential Remains
Catalysts About Tonix Pharmaceuticals Holding Tonix Pharmaceuticals Holding develops and commercializes medicines for conditions with unmet medical need, including fibromyalgia, major depressive disorder and Lyme disease prevention. What are the underlying business or industry changes driving this perspective?Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Here's Why We're Not Too Worried About Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Situation
NasdaqCM:TNXP 1 Year Share Price vs Fair Value Explore Tonix Pharmaceuticals Holding's Fair Values from the Community...Revenue & Expenses Breakdown
How Tonix Pharmaceuticals Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 26 | 29 | -160 | 126 | 64 |
| 31 Mar 26 | 18 | -147 | 106 | 55 |
| 31 Dec 25 | 13 | -124 | 88 | 44 |
| 30 Sep 25 | 10 | -99 | 68 | 36 |
| 30 Jun 25 | 10 | -81 | 50 | 36 |
| 31 Mar 25 | 10 | -132 | 41 | 35 |
| 31 Dec 24 | 10 | -130 | 40 | 40 |
| 30 Sep 24 | 11 | -135 | 36 | 49 |
| 30 Jun 24 | 12 | -149 | 37 | 61 |
| 31 Mar 24 | 10 | -99 | 37 | 73 |
| 31 Dec 23 | 8 | -117 | 35 | 87 |
| 30 Sep 23 | 4 | -123 | 31 | 94 |
| 30 Jun 23 | 0 | -124 | 30 | 95 |
| 31 Mar 23 | 0 | -123 | 30 | 90 |
| 31 Dec 22 | 0 | -117 | 30 | 82 |
| 30 Sep 22 | 0 | -112 | 29 | 79 |
| 30 Jun 22 | 0 | -102 | 27 | 70 |
| 31 Mar 22 | 0 | -98 | 26 | 72 |
| 31 Dec 21 | 0 | -92 | 23 | 69 |
| 30 Sep 21 | 0 | -80 | 21 | 59 |
| 30 Jun 21 | 0 | -73 | 19 | 54 |
| 31 Mar 21 | 0 | -64 | 17 | 47 |
| 31 Dec 20 | 0 | -52 | 14 | 36 |
| 30 Sep 20 | 0 | -46 | 12 | 30 |
| 30 Jun 20 | 0 | -42 | 12 | 26 |
| 31 Mar 20 | 0 | -34 | 11 | 19 |
| 31 Dec 19 | 0 | -31 | 11 | 18 |
| 30 Sep 19 | 0 | -31 | 10 | 18 |
| 30 Jun 19 | 0 | -28 | 10 | 16 |
| 31 Mar 19 | 0 | -29 | 9 | 16 |
| 31 Dec 18 | 0 | -29 | 9 | 18 |
| 30 Sep 18 | 0 | -24 | 8 | 16 |
| 30 Jun 18 | 0 | -24 | 8 | 17 |
| 31 Mar 18 | 0 | -23 | 8 | 16 |
| 31 Dec 17 | 0 | -21 | 8 | 13 |
| 30 Sep 17 | 0 | -23 | 9 | 15 |
| 30 Jun 17 | 0 | -25 | 9 | 15 |
| 31 Mar 17 | 0 | -30 | 9 | 21 |
| 31 Dec 16 | 0 | -39 | 10 | 29 |
| 30 Sep 16 | 0 | -45 | 12 | 33 |
| 30 Jun 16 | 0 | -50 | 13 | 39 |
| 31 Mar 16 | 0 | -52 | 13 | 39 |
| 31 Dec 15 | 0 | -48 | 13 | 36 |
Quality Earnings: TNXP is currently unprofitable.
Growing Profit Margin: TNXP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TNXP is unprofitable, and losses have increased over the past 5 years at a rate of 8.2% per year.
Accelerating Growth: Unable to compare TNXP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TNXP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (64.6%).
Return on Equity
High ROE: TNXP has a negative Return on Equity (-71.83%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 08:26 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tonix Pharmaceuticals Holding Corp. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Chiara Russo | Brean Capital Historical (Janney Montgomery) |
| David Buck | B. Riley Securities, Inc. |